Intellia Therapeutics' (NTLA) shares were down 1.3% in recent Thursday trading after the company reported a Q2 net loss of $0.98 per diluted share, narrower than its loss of $1.52 a year earlier.
Analysts polled by FactSet expected a loss of $1.02 per share.
Collaboration revenue for the quarter ended June 30 was $14.2 million, compared with $7.0 million a year earlier.
Analysts surveyed by FactSet expected $11.9 million.
The company said it had cash, cash equivalents, and marketable securities of $630.5 million as of June 30, which is expected to fund operations into H1 2027.
精彩评论